15/02/2022
Scientific
Publications
- ASCO 2022 Kiefer
- Oligon Dual Targeting Poster
- Oligon IO Poster
- EpCAM Aptamer-mediated Survivin Silencing Sensitized Cancer Stem Cells to Doxorubicin in a Breast Cancer Model
- Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors
- Gene Knockdown by EpCAM Aptamer–siRNA Chimeras Suppresses Epithelial Breast Cancers and Their Tumor-Initiating Cells
- Co-targeting EGFR and survivin with a bivalent aptamer-dual siRNA chimera effectively suppresses prostate cancer
- Targeting EGFR/HER2/HER3 with a Three-in-One Aptamer-siRNA Chimera Confers Superior Activity against HER2+ Breast Cancer
- The Use of Sensitive Chemical Antibodies for Diagnosis: Detection of Low Levels of Epcam in Breast Cancer
- CTLA4 aptamer delivers STAT3 siRNA to tumor-associated and malignant T cells
- ASCO 2022 Kiefer
- Oligon Dual Targeting Poster
- Oligon IO poster
- EpCAM Aptamer-mediated Survivin Silencing Sensitized Cancer Stem Cells to Doxorubicin in a Breast Cancer Model
- Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors
- Gene Knockdown by EpCAM Aptamer–siRNA Chimeras Suppresses Epithelial Breast Cancers and Their Tumor-Initiating Cells
- Co-targeting EGFR and survivin with a bivalent aptamer-dual siRNA chimera effectively suppresses prostate cancer
- Targeting EGFR/HER2/HER3 with a Three-in-One Aptamer-siRNA Chimera Confers Superior Activity against HER2+ Breast Cancer
- The Use of Sensitive Chemical Antibodies for Diagnosis: Detection of Low Levels of Epcam in Breast Cancer
- CTLA4 aptamer delivers STAT3 siRNA to tumor-associated and malignant T cells
